Literature DB >> 23092383

Harnessing the power of the immune system to target cancer.

Gregory Lizée1, Willem W Overwijk, Laszlo Radvanyi, Jianjun Gao, Padmanee Sharma, Patrick Hwu.   

Abstract

For many years, immunotherapeutic approaches for cancer held more promise than actual clinical benefit for the majority of patients. However, several recent key advances in tumor immunology have now turned the tide in favor of immunotherapy for the treatment of many different cancer types. In this review, we describe four of the most effective immunotherapeutic approaches currently used in the clinic: cancer vaccines, immunostimulatory agents, adoptive T cell therapy, and immune checkpoint blockade. In addition, we discuss some of the most promising future strategies that aim to utilize multiple immunotherapies or combine them with other approaches to more effectively target cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23092383     DOI: 10.1146/annurev-med-112311-083918

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  60 in total

1.  Big thinking for adjuvants.

Authors:  Eric L Dane; Darrell J Irvine
Journal:  Nat Biotechnol       Date:  2015-11       Impact factor: 54.908

Review 2.  Modeling the T cell immune response: a fascinating challenge.

Authors:  Penelope A Morel; James R Faeder; William F Hawse; Natasa Miskov-Zivanov
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-26       Impact factor: 2.745

Review 3.  Versatile CAR T-cells for cancer immunotherapy.

Authors:  Fuliang Chu; Jingjing Cao; Sattva S Neelalpu
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

4.  Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression in melanoma.

Authors:  Sherille D Bradley; Brenda Melendez; Amjad Talukder; Gregory Lizée
Journal:  Oncoimmunology       Date:  2015-08-25       Impact factor: 8.110

5.  Chemotherapeutic tumor microparticles combining low-dose irradiation reprogram tumor-promoting macrophages through a tumor-repopulating cell-curtailing pathway.

Authors:  Yanling Sun; Zu'an Zheng; Huafeng Zhang; Yuandong Yu; Jingwei Ma; Ke Tang; Pingwei Xu; Tiantian Ji; Xiaoyu Liang; Degao Chen; Xun Jin; Tianzhen Zhang; Zhixiong Long; Yuying Liu; Bo Huang
Journal:  Oncoimmunology       Date:  2017-03-31       Impact factor: 8.110

6.  HLA-Arena: A Customizable Environment for the Structural Modeling and Analysis of Peptide-HLA Complexes for Cancer Immunotherapy.

Authors:  Dinler A Antunes; Jayvee R Abella; Sarah Hall-Swan; Didier Devaurs; Anja Conev; Mark Moll; Gregory Lizée; Lydia E Kavraki
Journal:  JCO Clin Cancer Inform       Date:  2020-07

7.  A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.

Authors:  Drew C Deniger; Mei Li M Kwong; Anna Pasetto; Mark E Dudley; John R Wunderlich; Michelle M Langhan; Chyi-Chia Richard Lee; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2016-10-07       Impact factor: 12.531

Review 8.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Authors:  Audry Fernández; Liliana Oliver; Rydell Alvarez; Luis E Fernández; Kelvin P Lee; Circe Mesa
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.

Authors:  Aaron M Miller; Milad Bahmanof; Dietmar Zehn; Ezra E W Cohen; Stephen P Schoenberger
Journal:  Cancer Immunol Res       Date:  2018-11-27       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.